Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (...

FDA Recall #D-0188-2025 — Class II — December 30, 2024

Recall #D-0188-2025 Date: December 30, 2024 Classification: Class II Status: Ongoing

Product Description

Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reason for Recall

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Recalling Firm

Rising Pharma Holding, Inc. — East Brunswick, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

42,527 bottles

Distribution

Nationwide

Code Information

a) Lot# DT3023051A, exp. date Apr-25; b) DT3023025A, exp. date Jan-25

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated